In this article, we will list the 5 Most Undervalued Biotech Stocks to Buy Right Now. Please visit 8 Most Undervalued Biotech Stocks to Buy Right Now if you would like to see the extended list and the methodology behind it.
5. ADMA Biologics Inc. (NASDAQ:ADMA)
ADMA Biologics Inc. (NASDAQ:ADMA) is one of the most undervalued biotech stocks to buy right now. Cantor Fitzgerald downgraded ADMA Biologics Inc. (NASDAQ:ADMA) to Neutral from Overweight on March 26, without assigning a price target. The firm stated that it spoke with a number of investors after a short report’s claim that ADMA Biologics Inc. (NASDAQ:ADMA) is boosting Asceniv revenues through channel stuffing, and stated that investors are disappointed over the company’s response and lack of direct communication after the report. The firm further contended that although the company put out a statement, they were “hoping to have more specific feedback addressing the direct claims in the report”. The firm also cited the lack of clarity and concerns associated with the increased days’ sales outstanding and accounts receivable for the downgrade.
ADMA Biologics Inc. (NASDAQ:ADMA) issued a statement refuting the allegations by Culper Research on March 27, calling them “unsubstantiated, misleading, and inaccurate”. The company did so to “alleviate confusion in the marketplace” regarding the company’s operations and business practices.
ADMA Biologics Inc. (NASDAQ:ADMA) is a biopharmaceutical company that manufactures, markets, and develops specialty plasma-derived biologics. Its operations are divided into the following business segments: ADMA BioManufacturing and Plasma Collection Center.
4. Royalty Pharma Plc (NASDAQ:RPRX)
Royalty Pharma Plc (NASDAQ:RPRX) is one of the most undervalued biotech stocks to buy right now. Royalty Pharma Plc (NASDAQ:RPRX) announced on April 17 that its board of directors approved the payment of a dividend for the second quarter of 2026 of $0.235 per Class A ordinary share. Management stated that the dividend will be paid on June 10, 2026, to shareholders of record at the close of business on May 15, 2026. In a separate development, Morgan Stanley lifted the price target on Royalty Pharma Plc (NASDAQ:RPRX) to $63 from $61 on April 10, reiterating an Overweight rating on the shares and adjusting models among the stocks under its biopharma coverage for IQVIA trends as well as intra-quarter updates ahead of the group’s fiscal Q1 earnings reports.
Royalty Pharma Plc (NASDAQ:RPRX) also announced on March 30 a research and development (R&D) co-funding agreement with Johnson & Johnson for a total of $500 million in 2026 and 2027, aimed at advancing the development of JNJ-4804, an investigational medicine for autoimmune diseases.
Royalty Pharma Plc (NASDAQ:RPRX) funds innovation in the biopharmaceutical industry and buys biopharmaceutical royalties. It collaborates with innovators from research hospitals, non-profits, and academic institutions through small and mid-cap biotech companies to global pharma companies. The company funds innovation in the industry both directly, by partnering with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly, by acquiring existing royalties from the original innovators.
3. Incyte Corporation (NASDAQ:INCY)
Incyte Corporation (NASDAQ:INCY) is one of the most undervalued biotech stocks to buy right now. RBC Capital raised the price target on Incyte Corporation (NASDAQ:INCY) to $95 from $92 on April 7, reiterating a Sector Perform rating on the shares. The rating update came as part of a broader research note previewing the fiscal Q1 results in the Biotech sector, with the firm telling investors in the research note that factors such as seasonal headwinds around gross/net, reimbursement resets, and fewer selling days may be exacerbated in fiscal Q1 by weather impact. This holds especially true for launching and in-clinic products. However, RBC Capital added that the robust return of M&A, along with clarity on limited tariff/Most Favored Nation drug pricing impacts, may prove helpful in offsetting both this and broader macro volatility while keeping sector perceptions favorable.
For additional perspective, in its financial results for fiscal Q4 and the full year ended December 31, 2025, Incyte Corporation (NASDAQ:INCY) reported a total revenue of $1.51 billion for the quarter, up 28% compared to the prior year period. Management attributed the growth to an increase in total net product revenue and milestone and contract revenue. Total revenue for the full year reached $5.14 billion, reflecting a growth of 21% compared to the prior year period and primarily driven by growth in the total net product revenue and milestone and contract revenue.
Incyte Corporation (NASDAQ:INCY) is a biopharmaceutical company that discovers, develops, and commercializes proprietary therapeutics, focusing on oncology, hematology, inflammation, and autoimmunity therapeutic areas.
2. Jazz Pharmaceuticals (NASDAQ:JAZZ)
Jazz Pharmaceuticals (NASDAQ:JAZZ) is one of the most undervalued biotech stocks to buy right now. On April 10, Raymond James resumed coverage of Jazz Pharmaceuticals (NASDAQ:JAZZ) with an Outperform rating and set a price target of $227. The firm told investors that the Jazz story has travelled beyond the narrative of “it looks inexpensive/fairly valued, but where can I get upside?” since adding greater visibility to the tail value of the Epidiolex franchise and zanidatamab delivering “highly competitive” data in gastroesophageal adenocarcinoma.
Jazz Pharmaceuticals (NASDAQ:JAZZ) also received a rating update from Piper Sandler on March 19, with the firm lifting the price target on the stock to $232 from $219 while maintaining an Overweight rating on the shares. The firm stated that moving further into 2026, it continues to view the company as undervalued at a current EV/2026E EBITDA of only seven times in the context of a company that has strong visibility into double-digit overall top-line growth starting in 2027. Piper added that the competitive dynamics associated with the oxybate franchise are not lost on it, but it does not envision said dynamics throwing a wrench into its thinking regarding Jazz Pharmaceuticals’ (NASDAQ:JAZZ) overall growth profile.
Jazz Pharmaceuticals (NASDAQ:JAZZ) develops medicines for serious diseases. Its primary marketed products include Xywav, Xyrem oral solution, Epidiolex oral solution, Rylaze, Zepzelca, Defitelio, and Vyxeos liposome for injection. These medicines treat excess daytime sleepiness (EDS) in narcolepsy patients seven years of age or older, tepatic veno-occlusive disease (VOD), and other ailments.
1. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the most undervalued biotech stocks to buy right now. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced on April 13 a collaboration with Telix Pharmaceuticals Limited aimed at the joint development and commercialization of next-generation radiopharmaceutical therapies. Management stated that the collaboration brings together Regeneron Pharmaceuticals’ (NASDAQ:REGN) biologics expertise, including bispecific antibody discovery, with Telix’s radiopharmaceutical development platform, global manufacturing capabilities, and supply chain infrastructure. It further reported that the collaboration will include several solid tumor targets from Regeneron Pharmaceuticals’ (NASDAQ:REGN) portfolio of antibodies, generated from VelocImmune® mice. The agreement also aims at developing radio-diagnostics to support patient selection and treatment response assessment, in line with the two companies’ shared commitment to precision oncology.
The terms of the agreement state that Telix will receive an upfront cash payment of $40 million from Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for access to its radiopharmaceutical manufacturing platform for four initial therapeutic programs. The latter will have the option to expand to include four additional programs with additional upfront payments.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a pharmaceutical company that develops, discovers, and commercializes therapies for several diseases, including cancer, eye disorders, and allergic conditions. It has relied on two primary products to drive top-line growth in the past years: Dupixent and Eylea.
While we acknowledge the potential of REGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than REGN and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
